Association of Systemic Inflammation Index and Body Mass Index With Survival in Patients With Renal Cell Cancer Treated With Nivolumab.

CONCLUSIONS: Normal BMI combined with inflammation tripled the risk of death, suggesting that these biomarkers are critical prognostic factors for OS in patients with RCC treated with nivolumab.
PMID: 30967420 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 8, 2019 Category: Cancer & Oncology Authors: De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli P, Ferraù F, Crinò L, Frassoldati A, Marchetti P, Mini E, Scoppola A, Verusio C, Fornarini G, Cartenì G, Caserta C, Sternberg C Tags: Clin Cancer Res Source Type: research